Evropska unija - slovenščina - EMA (European Medicines Agency)

accord healthcare s.l.u. - doxorubicin hydrochloride, liposomal - ovarian neoplasms; sarcoma, kaposi; multiple myeloma - doxorubicin - zolsketil pegylated liposomal is a medicine used to treat the following types of cancer in adults:• breast cancer that has spread to other parts of the body in patients at risk of heart problems. zolsketil pegylated liposomal is used on its own for this disease;• advanced ovarian cancer in women whose previous treatment including a platinum-based cancer medicine has stopped working;• multiple myeloma (a cancer of the white blood cells in the bone marrow), in patients with progressive disease who have received at least one other treatment in the past and have already had, or are unsuitable for, a bone marrow transplantation. zolsketil pegylated liposomal is used in combination with bortezomib (another cancer medicine);• kaposi’s sarcoma in patients with aids who have a very damaged immune system. kaposi’s sarcoma is a cancer that causes abnormal tissue to grow under the skin, on moist body surfaces or on internal organs. zolsketil pegylated liposomal contains the active substance doxorubicin and is a ‘hybrid medicine’. this means that it is similar to a ‘reference medicine’ containing the same active substance called adriamycin. however, in zolsketil pegylated liposomal the active substance is enclosed in tiny fatty spheres called liposomes, whereas this is not the case for adriamycin.

Evropska unija - slovenščina - EMA (European Medicines Agency)

yes pharmaceutical development services gmbh - doksorubicinijev klorid - breast neoplasms; ovarian neoplasms; multiple myeloma; sarcoma, kaposi - antineoplastična sredstva - celdoxome pegylated liposomal is indicated in adults:as monotherapy for patients with metastatic breast cancer, where there is an increased cardiac risk. or treatment of advanced ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen. in combination with bortezomib for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant. for treatment of aids-related kaposi’s sarcoma (ks) in patients with low cd4 counts (< 200 cd4 lymphocytes/mm3) and extensive mucocutaneous or visceral disease. celdoxome pegylated liposomal may be used as first-line systemic chemotherapy, or as second line chemotherapy in aids-ks patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and standard doxorubicin (or other anthracycline).

Evropska unija - slovenščina - EMA (European Medicines Agency)

orion corporation - dexmedetomidine hydrochloride - zavestna sedacija - psiholeptiki - za sedacijo odraslih bolnikov z intenzivno nego, ki zahtevajo stopnjo sedacije ne globlje od vzburjenja kot odziv na verbalno stimulacijo (kar ustreza richmondovemu agitacijsko sedimentacijsko lestvici (rass) od 0 do -3).

Evropska unija - slovenščina - EMA (European Medicines Agency)

gilead sciences international ltd  - emtricitabine, rilpivirine hydrochloride, tenofovir disoproxil fumarate - okužbe z virusom hiv - antivirusi za sistemsko uporabo - eviplera je indicirano za zdravljenje odraslih, okuženih z virusom človeške imunske pomanjkljivosti tipa 1 (hiv-1) brez znane mutacije, povezane z odpornostjo-nukleozidni reverzne transkriptaze (nnrti) inhibitor razred, so ali emtricitabine, in z virusna obremenitev ≤ 100.000 hiv-1 rna kopij/ml. kot pri drugih protiretrovirusnih zdravilih je treba testiranje genotipske odpornosti in / ali zgodovinske podatke o odpornosti voditi pri uporabi zdravila eviplera.

Evropska unija - slovenščina - EMA (European Medicines Agency)

dipharma arzneimittel gmbh - sapropterin dihydrochloride - fenilketonurije - drugi zdravljene bolezni prebavil in presnove izdelki, - sapropterin dipharma is indicated for the treatment of hyperphenylalaninaemia (hpa) in adults and paediatric patients of all ages with phenylketonuria (pku) who have been shown to be responsive to such treatment. sapropterin dipharma is also indicated for the treatment of hyperphenylalaninaemia (hpa) in adults and paediatric patients of all ages with tetrahydrobiopterin (bh4) deficiency who have been shown to be responsive to such treatment.

Evropska unija - slovenščina - EMA (European Medicines Agency)

eli lilly nederland b.v. - duloksetin - diabetične nevropatije - psychoanaleptics, - zdravljenje diabetične periferne nevropatske bolečine. ariclaim je navedeno v odrasli.

Evropska unija - slovenščina - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - duloksetin - diabetične nevropatije - psychoanaleptics, - zdravljenje diabetične periferne nevropatske bolečine pri odraslih.

Evropska unija - slovenščina - EMA (European Medicines Agency)

zentiva, k.s. - duloksetin - neuralgia; depressive disorder, major; anxiety disorders; diabetes mellitus - drugi antidepresivi - zdravljenje depresivne motnje, diabetične nevropatske bolečine, anksiozne motnje. duloxetine zentiva je navedeno v odrasli.

Evropska unija - slovenščina - EMA (European Medicines Agency)

ecuphar - meloksikam - proti vnetno in antirheumatic izdelki - dogs; cats - ustni vzmetenje:psi:lajšanje vnetja in bolečine v akutni in kronični mišično-skeletne motnje. raztopina za injiciranje:psi:lajšanje vnetja in bolečine v akutni in kronični mišično-skeletne motnje. zmanjšanje pooperativne bolečine in vnetja po ortopedski in operaciji mehkega tkiva. mačke:zmanjšanje pooperativne bolečine po ovariohysterectomy in manjše mehka tkiva operacijo.

Evropska unija - slovenščina - EMA (European Medicines Agency)

takeda pharma a/s - fentanil citrat - pain; cancer - analgetiki - zdravilo instanyl je indicirano za zdravljenje prebijajoče bolečine pri odraslih, ki že prejemajo vzdrževalno opioidno terapijo za kronično bolečino pri raku. prebojna bolečina je prehodno poslabšanje bolečine, ki se pojavi na ozadju kontinuirane bolečine, ki jo sicer nadzira.  patients receiving maintenance opioid therapy are those who are taking at least 60 mg of oral morphine daily, at least 25 micrograms of transdermal fentanyl per hour, at least 30 mg oxycodone daily, at least 8 mg of oral hydromorphone daily or an equianalgesic dose of another opioid for a week or longer.